Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

IDAI vs ACXP vs AIOT vs XTLB vs IDCC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
IDAI
T Stamp Inc.

Software - Application

TechnologyNASDAQ • US
Market Cap$3M
5Y Perf.-64.3%
ACXP
Acurx Pharmaceuticals, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$5M
5Y Perf.-95.3%
AIOT
PowerFleet, Inc.

Communication Equipment

TechnologyNASDAQ • US
Market Cap$463M
5Y Perf.-25.6%
XTLB
XTL Biopharmaceuticals Ltd.

Biotechnology

HealthcareNASDAQ • IL
Market Cap$294K
5Y Perf.-72.5%
IDCC
InterDigital, Inc.

Software - Application

TechnologyNASDAQ • US
Market Cap$7.18B
5Y Perf.+139.2%

IDAI vs ACXP vs AIOT vs XTLB vs IDCC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
IDAI logoIDAI
ACXP logoACXP
AIOT logoAIOT
XTLB logoXTLB
IDCC logoIDCC
IndustrySoftware - ApplicationBiotechnologyCommunication EquipmentBiotechnologySoftware - Application
Market Cap$3M$5M$463M$294K$7.18B
Revenue (TTM)$4M$0.00$436M$451K$829M
Net Income (TTM)$-12M$-7.97B$-32M$-1M$366M
Gross Margin60.0%55.2%26.4%83.4%
Operating Margin-183.3%1.7%-481.6%49.6%
Forward P/E38.8x
Total Debt$4M$0.00$287M$138K$506M
Cash & Equiv.$3M$7.56B$49M$371K$739M

IDAI vs ACXP vs AIOT vs XTLB vs IDCCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

IDAI
ACXP
AIOT
XTLB
IDCC
StockJun 24May 26Return
T Stamp Inc. (IDAI)10035.7-64.3%
Acurx Pharmaceutica… (ACXP)1004.7-95.3%
PowerFleet, Inc. (AIOT)10074.4-25.6%
XTL Biopharmaceutic… (XTLB)10027.5-72.5%
InterDigital, Inc. (IDCC)100239.2+139.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: IDAI vs ACXP vs AIOT vs XTLB vs IDCC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: IDCC leads in 4 of 6 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. PowerFleet, Inc. is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
IDAI
T Stamp Inc.
The Technology Pick

IDAI plays a supporting role in this comparison — it may shine differently against other peers.

Best for: technology exposure
ACXP
Acurx Pharmaceuticals, Inc.
The Healthcare Pick

ACXP lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
AIOT
PowerFleet, Inc.
The Growth Play

AIOT is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 66.3%, EPS growth 60.6%, 3Y rev CAGR 42.2%
  • 66.3% revenue growth vs XTLB's -173.2%
  • 22.2% yield, 1-year raise streak, vs IDCC's 0.6%, (3 stocks pay no dividend)
Best for: growth exposure
XTLB
XTL Biopharmaceuticals Ltd.
The Healthcare Pick

Among these 5 stocks, XTLB doesn't own a clear edge in any measured category.

Best for: healthcare exposure
IDCC
InterDigital, Inc.
The Income Pick

IDCC carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 4 yrs, beta 1.12, yield 0.6%
  • 436.7% 10Y total return vs AIOT's -28.7%
  • Lower volatility, beta 1.12, Low D/E 45.9%, current ratio 1.84x
  • Beta 1.12, yield 0.6%, current ratio 1.84x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthAIOT logoAIOT66.3% revenue growth vs XTLB's -173.2%
Quality / MarginsIDCC logoIDCC44.2% margin vs IDAI's -316.4%
Stability / SafetyIDCC logoIDCCBeta 1.12 vs AIOT's 2.70, lower leverage
DividendsAIOT logoAIOT22.2% yield, 1-year raise streak, vs IDCC's 0.6%, (3 stocks pay no dividend)
Momentum (1Y)IDCC logoIDCC+32.4% vs ACXP's -70.1%
Efficiency (ROA)IDCC logoIDCC17.7% ROA vs ACXP's -413.5%

IDAI vs ACXP vs AIOT vs XTLB vs IDCC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

IDAIT Stamp Inc.
FY 2024
Professional Services (Over Time)
72.5%$2M
License Fees (Over Time)
27.5%$573,000
ACXPAcurx Pharmaceuticals, Inc.

Segment breakdown not available.

AIOTPowerFleet, Inc.
FY 2024
Service
62.8%$84M
Product
37.2%$50M
XTLBXTL Biopharmaceuticals Ltd.

Segment breakdown not available.

IDCCInterDigital, Inc.
FY 2025
Revenues
99.9%$834M
Revenue - Other
0.1%$529,000

IDAI vs ACXP vs AIOT vs XTLB vs IDCC — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLIDCCLAGGINGXTLB

Income & Cash Flow (Last 12 Months)

IDCC leads this category, winning 4 of 6 comparable metrics.

IDCC and ACXP operate at a comparable scale, with $829M and $0 in trailing revenue. IDCC is the more profitable business, keeping 44.2% of every revenue dollar as net income compared to IDAI's -3.2%. On growth, IDAI holds the edge at +70.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricIDAI logoIDAIT Stamp Inc.ACXP logoACXPAcurx Pharmaceuti…AIOT logoAIOTPowerFleet, Inc.XTLB logoXTLBXTL Biopharmaceut…IDCC logoIDCCInterDigital, Inc.
RevenueTrailing 12 months$4M$0$436M$451,000$829M
EBITDAEarnings before interest/tax-$6M$35,910$69M-$1M$489M
Net IncomeAfter-tax profit-$12M-$8.0B-$32M-$1M$366M
Free Cash FlowCash after capex-$8M$4.6B$3M$0$580M
Gross MarginGross profit ÷ Revenue+60.0%+55.2%+26.4%+83.4%
Operating MarginEBIT ÷ Revenue-183.3%+1.7%-4.8%+49.6%
Net MarginNet income ÷ Revenue-3.2%-7.4%-2.3%+44.2%
FCF MarginFCF ÷ Revenue-2.2%+0.6%-3.7%+70.0%
Rev. Growth (YoY)Latest quarter vs prior year+70.7%+47.4%-2.4%
EPS Growth (YoY)Latest quarter vs prior year+32.1%+98.2%-25.5%+20.0%-38.0%
IDCC leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — ACXP and AIOT and XTLB and IDCC each lead in 1 of 4 comparable metrics.

On an enterprise value basis, IDCC's 12.9x EV/EBITDA is more attractive than AIOT's 44.2x.

MetricIDAI logoIDAIT Stamp Inc.ACXP logoACXPAcurx Pharmaceuti…AIOT logoAIOTPowerFleet, Inc.XTLB logoXTLBXTL Biopharmaceut…IDCC logoIDCCInterDigital, Inc.
Market CapShares × price$3M$5M$463M$293,767$7.2B
Enterprise ValueMkt cap + debt − cash$4M-$7.6B$701M$60,767$6.9B
Trailing P/EPrice ÷ TTM EPS-0.22x-0.40x-7.91x-0.28x23.62x
Forward P/EPrice ÷ next-FY EPS est.38.81x
PEG RatioP/E ÷ EPS growth rate0.45x
EV / EBITDAEnterprise value multiple44.16x12.91x
Price / SalesMarket cap ÷ Revenue0.89x1.28x0.65x8.61x
Price / BookPrice ÷ Book value/share0.86x0.00x0.91x0.05x8.73x
Price / FCFMarket cap ÷ FCF13.58x
Evenly matched — ACXP and AIOT and XTLB and IDCC each lead in 1 of 4 comparable metrics.

Profitability & Efficiency

IDCC leads this category, winning 6 of 9 comparable metrics.

IDCC delivers a 33.4% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $-6 for ACXP. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to IDAI's 1.30x. On the Piotroski fundamental quality scale (0–9), IDCC scores 6/9 vs IDAI's 1/9, reflecting solid financial health.

MetricIDAI logoIDAIT Stamp Inc.ACXP logoACXPAcurx Pharmaceuti…AIOT logoAIOTPowerFleet, Inc.XTLB logoXTLBXTL Biopharmaceut…IDCC logoIDCCInterDigital, Inc.
ROE (TTM)Return on equity-189.5%-6.0%-6.6%-25.5%+33.4%
ROA (TTM)Return on assets-105.4%-4.1%-3.4%-17.7%+17.7%
ROICReturn on invested capital-2.2%-4.3%-54.1%+40.9%
ROCEReturn on capital employed-194.9%-5.1%-50.7%+38.1%
Piotroski ScoreFundamental quality 0–913336
Debt / EquityFinancial leverage1.30x0.64x0.03x0.46x
Net DebtTotal debt minus cash$1M-$7.6B$238M-$233,000-$233M
Cash & Equiv.Liquid assets$3M$7.6B$49M$371,000$739M
Total DebtShort + long-term debt$4M$0$287M$138,000$506M
Interest CoverageEBIT ÷ Interest expense-22.08x0.47x-13.31x11.48x
IDCC leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

IDCC leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in IDCC five years ago would be worth $40,308 today (with dividends reinvested), compared to $95 for IDAI. Over the past 12 months, IDCC leads with a +32.4% total return vs ACXP's -70.1%. The 3-year compound annual growth rate (CAGR) favors IDCC at 52.1% vs ACXP's -67.4% — a key indicator of consistent wealth creation.

MetricIDAI logoIDAIT Stamp Inc.ACXP logoACXPAcurx Pharmaceuti…AIOT logoAIOTPowerFleet, Inc.XTLB logoXTLBXTL Biopharmaceut…IDCC logoIDCCInterDigital, Inc.
YTD ReturnYear-to-date-38.4%-23.2%-35.2%+11.3%-14.1%
1-Year ReturnPast 12 months+20.9%-70.1%-32.7%-50.9%+32.4%
3-Year ReturnCumulative with dividends-87.5%-96.5%-28.7%-45.7%+251.7%
5-Year ReturnCumulative with dividends-99.1%-98.7%-28.7%-80.4%+303.1%
10-Year ReturnCumulative with dividends+102.4%-98.7%-28.7%-87.3%+436.7%
CAGR (3Y)Annualised 3-year return-50.0%-67.4%-10.7%-18.4%+52.1%
IDCC leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

IDCC leads this category, winning 2 of 2 comparable metrics.

IDCC is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than AIOT's 2.70 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IDCC currently trades 67.6% from its 52-week high vs ACXP's 10.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricIDAI logoIDAIT Stamp Inc.ACXP logoACXPAcurx Pharmaceuti…AIOT logoAIOTPowerFleet, Inc.XTLB logoXTLBXTL Biopharmaceut…IDCC logoIDCCInterDigital, Inc.
Beta (5Y)Sensitivity to S&P 5001.99x2.42x2.70x1.71x1.12x
52-Week HighHighest price in past year$5.28$21.00$6.07$10.28$412.60
52-Week LowLowest price in past year$1.80$1.33$2.77$1.05$205.78
% of 52W HighCurrent price vs 52-week peak+47.2%+10.1%+56.0%+26.0%+67.6%
RSI (14)Momentum oscillator 0–10049.140.952.257.030.8
Avg Volume (50D)Average daily shares traded43K3.6M1.6M2.4M393K
IDCC leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — AIOT and IDCC each lead in 1 of 2 comparable metrics.

Analyst consensus: AIOT as "Buy", IDCC as "Buy". Consensus price targets imply 135.3% upside for AIOT (target: $8) vs 52.5% for IDCC (target: $425). For income investors, AIOT offers the higher dividend yield at 22.15% vs IDCC's 0.63%.

MetricIDAI logoIDAIT Stamp Inc.ACXP logoACXPAcurx Pharmaceuti…AIOT logoAIOTPowerFleet, Inc.XTLB logoXTLBXTL Biopharmaceut…IDCC logoIDCCInterDigital, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$8.00$425.00
# AnalystsCovering analysts516
Dividend YieldAnnual dividend ÷ price+22.2%+0.6%
Dividend StreakConsecutive years of raises14
Dividend / ShareAnnual DPS$0.75$1.76
Buyback YieldShare repurchases ÷ mkt cap+2.1%+100.0%+0.6%0.0%+1.4%
Evenly matched — AIOT and IDCC each lead in 1 of 2 comparable metrics.
Key Takeaway

IDCC leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.

Best OverallInterDigital, Inc. (IDCC)Leads 4 of 6 categories
Loading custom metrics...

IDAI vs ACXP vs AIOT vs XTLB vs IDCC: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is IDAI or ACXP or AIOT or XTLB or IDCC a better buy right now?

For growth investors, InterDigital, Inc.

(IDCC) is the stronger pick with -4. 0% revenue growth year-over-year, versus -32. 4% for T Stamp Inc. (IDAI). InterDigital, Inc. (IDCC) offers the better valuation at 23. 6x trailing P/E (38. 8x forward), making it the more compelling value choice. Analysts rate PowerFleet, Inc. (AIOT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — IDAI or ACXP or AIOT or XTLB or IDCC?

Over the past 5 years, InterDigital, Inc.

(IDCC) delivered a total return of +303. 1%, compared to -99. 1% for T Stamp Inc. (IDAI). Over 10 years, the gap is even starker: IDCC returned +436. 7% versus ACXP's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — IDAI or ACXP or AIOT or XTLB or IDCC?

By beta (market sensitivity over 5 years), InterDigital, Inc.

(IDCC) is the lower-risk stock at 1. 12β versus PowerFleet, Inc. 's 2. 70β — meaning AIOT is approximately 142% more volatile than IDCC relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 130% for T Stamp Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — IDAI or ACXP or AIOT or XTLB or IDCC?

By revenue growth (latest reported year), InterDigital, Inc.

(IDCC) is pulling ahead at -4. 0% versus -32. 4% for T Stamp Inc. (IDAI). On earnings-per-share growth, the picture is similar: Acurx Pharmaceuticals, Inc. grew EPS 69. 8% year-over-year, compared to -2. 2% for InterDigital, Inc.. Over a 3-year CAGR, AIOT leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — IDAI or ACXP or AIOT or XTLB or IDCC?

InterDigital, Inc.

(IDCC) is the more profitable company, earning 48. 8% net margin versus -344. 1% for T Stamp Inc. — meaning it keeps 48. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDCC leads at 55. 3% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — IDCC leads at 80. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is IDAI or ACXP or AIOT or XTLB or IDCC more undervalued right now?

Analyst consensus price targets imply the most upside for AIOT: 135.

3% to $8. 00.

07

Which pays a better dividend — IDAI or ACXP or AIOT or XTLB or IDCC?

In this comparison, AIOT (22.

2% yield), IDCC (0. 6% yield) pay a dividend. IDAI, ACXP, XTLB do not pay a meaningful dividend and should not be held primarily for income.

08

Is IDAI or ACXP or AIOT or XTLB or IDCC better for a retirement portfolio?

For long-horizon retirement investors, InterDigital, Inc.

(IDCC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12), 0. 6% yield, +436. 7% 10Y return). Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IDCC: +436. 7%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between IDAI and ACXP and AIOT and XTLB and IDCC?

These companies operate in different sectors (IDAI (Technology) and ACXP (Healthcare) and AIOT (Technology) and XTLB (Healthcare) and IDCC (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IDAI is a small-cap quality compounder stock; ACXP is a small-cap quality compounder stock; AIOT is a small-cap income-oriented stock; XTLB is a small-cap quality compounder stock; IDCC is a small-cap quality compounder stock. AIOT, IDCC pay a dividend while IDAI, ACXP, XTLB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

IDAI

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 35%
  • Gross Margin > 35%
Run This Screen
Stocks Like

ACXP

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

AIOT

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 23%
  • Gross Margin > 33%
Run This Screen
Stocks Like

XTLB

Quality Business

  • Sector: Healthcare
  • Market Cap > $20B
  • Gross Margin > 15%
Run This Screen
Stocks Like

IDCC

Quality Mega-Cap Compounder

  • Sector: Technology
  • Market Cap > $100B
  • Net Margin > 26%
  • Dividend Yield > 0.5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.